We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

Back to rankings

119 hedge funds and large institutions have $424M invested in Keryx Biopharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $6.38M | Put options by funds: $3.8M

24% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 29

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

6% more capital invested

Capital invested by funds: $399M → $424M (+$25.1M)

3% less funds holding

Funds holding: 123 → 119 (-4)

Holders
119
Holders Change
-4
Holders Change %
-3.25%
% of All Funds
2.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
36
Reduced
29
Closed
18
Calls
$6.38M
Puts
$3.8M
Net Calls
+$2.59M
Net Calls Change
+$3.89M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$29.6M
2
CLM
ClearBridge LLC (Maryland)
Maryland
+$7.14M
3
OWIM
Old West Investment Management
California
+$3.39M
4
State Street
State Street
Massachusetts
+$3.19M
5
Millennium Management
Millennium Management
New York
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$7.57M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.57M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$2.49M
4
QIM
Quantitative Investment Management
Virginia
-$1.17M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Canada Life
101
Canada Life
Manitoba, Canada
$61K – – –
MC
102
Moors & Cabot
Massachusetts
$61K +$54.8K +10,000 New
ClearBridge Investments
103
ClearBridge Investments
New York
$45K +$18.2K +3,319 +83%
AIP
104
Ameritas Investment Partners
Nebraska
$38K +$33.7K +6,152 New
IA
105
IFP Advisors
Florida
$37K – – –
LTFS
106
Ladenburg Thalmann Financial Services
Florida
$36K – – –
Zurich Cantonal Bank
107
Zurich Cantonal Bank
Switzerland
$20K – – –
DADC
108
D.A. Davidson & Co
Montana
$16K -$4.38K -800 -23%
AF
109
Allworth Financial
California
$12K – – –
BNP Paribas Financial Markets
110
BNP Paribas Financial Markets
France
$10.1K -$21.9K -3,999 -71%
JP Morgan Chase
111
JP Morgan Chase
New York
$8K -$1.09M -198,462 -99%
Nisa Investment Advisors
112
Nisa Investment Advisors
Missouri
$8K -$1.64K -300 -19%
CFA
113
CT Financial Advisors
Pennsylvania
$6.38K – – –
JCM
114
Jacobi Capital Management
Pennsylvania
$6K +$5.48K +1,000 New
MAM
115
Meeder Asset Management
Ohio
$5K +$4.64K +847 New
SEI Investments
116
SEI Investments
Pennsylvania
$3K -$453K -82,700 -99%
FANJ
117
Financial Architects (New Jersey)
New Jersey
$2K – – –
GAM
118
Gemmer Asset Management
California
$1K – – –
SPIA
119
Steward Partners Investment Advisory
New York
$1K – – –
DM
120
Deerfield Management
New York
– -$7.57M -1,291,531 Closed
HS
121
HighVista Strategies
Massachusetts
– -$1M -171,300 Closed
GAM
122
Gotham Asset Management
New York
– -$450K -76,726 Closed
VFA
123
Virtus Fund Advisers
Connecticut
– -$327K -55,878 Closed
WC
124
Woodstock Corp
Massachusetts
– -$276K -47,017 Closed
CWG
125
C WorldWide Group
Denmark
– -$152K -26,000 Closed
2 3 4
5
6

KERX Hedge Fund Activity: Q1 2017 in Review

119 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2017, worth a combined $424M — up 6.3% from $399M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new KERX positions and 18 closed out — a net gain of 2 holders — while 36 added to existing stakes and 29 trimmed.

The largest buyer was BlackRock, adding an estimated $29.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.57M sold.

  • 119 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2017, down from 123 in Q4 2016.
  • Funds reported $424M of Keryx Biopharmaceuticals Inc stock for Q1 2017, up 6.3% quarter-over-quarter.
  • 20 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2017 and 18 closed out, a net change of +2 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $29.6M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q1 2017 was Deerfield Management, an estimated $7.57M sold.

Based on aggregated 13F filings for Q1 2017.